NIH awards SBIR grant to AVM for lymphoma drug research 25-Aug-2022 By Jenni Spinner The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
AstraZeneca to buy blood cancer focused biotech in deal valued at up to $1.27bn 05-Jul-2022 By Jane Byrne AstraZeneca is to acquire US-based blood cancer specialist, TeneoTwo, in a deal worth around US$1.27bn.